Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma
Background and objectives COVID‐19 convalescent plasma is an experimental treatment against SARS‐CoV‐2. The aim of this study is to assess the impact of different pathogen reduction methods on the levels and virus neutralizing activity of the specific antibodies against SARS‐CoV2 in convalescent pla...
Gespeichert in:
| Veröffentlicht in: | Vox sanguinis 2021-07, Vol.116 (6), p.665-672 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 672 |
|---|---|
| container_issue | 6 |
| container_start_page | 665 |
| container_title | Vox sanguinis |
| container_volume | 116 |
| creator | Kostin, Alexander I. Lundgren, Maria N. Bulanov, Andrey Y. Ladygina, Elena A. Chirkova, Karina S. Gintsburg, Alexander L. Logunov, Denis Y. Dolzhikova, Inna V. Shcheblyakov, Dmitry V. Borovkova, Natalia V. Godkov, Mikhail A. Bazhenov, Alexey I. Shustov, Valeriy V. Bogdanova, Alina S. Kamalova, Alina R. Ganchin, Vladimir V. Dombrovskiy, Eugene A. Volkov, Stanislav E. Drozdova, Nataliya E. Petrikov, Sergey S. |
| description | Background and objectives
COVID‐19 convalescent plasma is an experimental treatment against SARS‐CoV‐2. The aim of this study is to assess the impact of different pathogen reduction methods on the levels and virus neutralizing activity of the specific antibodies against SARS‐CoV2 in convalescent plasma.
Materials and methods
A total of 140 plasma doses collected by plasmapheresis from COVID‐19 convalescent donors were subjected to pathogen reduction by three methods: methylene blue (M)/visible light, riboflavin (R)/UVB and amotosalen (A)/UVA. To conduct a paired comparison, individual plasma doses were divided into 2 samples that were subjected to one of these methods. The titres of SARS‐CoV2 neutralizing antibodies (NtAbs) and levels of specific immunoglobulins to RBD, S‐ and N‐proteins of SARS‐CoV‐2 were measured before and after pathogen reduction.
Results
The methods reduced NtAbs titres differently: among units with the initial titre 80 or above, 81% of units remained unchanged and 19% decreased by one step after methylene blue; 60% were unchanged and 40% decreased by one step after amotosalen; after riboflavin 43% were unchanged and 50% (7%, respectively) had a one‐step (two‐step, respectively) decrease. Paired two‐sample comparisons (M vs. A, M vs. R and A vs. R) revealed that the largest statistically significant decrease in quantity and activity of the specific antibodies resulted from the riboflavin treatment.
Conclusion
Pathogen reduction with methylene blue or with amotosalen provides the greater likelihood of preserving the immunological properties of the COVID‐19 convalescent plasma compared to riboflavin. |
| doi_str_mv | 10.1111/vox.13056 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8250394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2553427678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5126-4af6b0f0d1d585bf7aa55783adcb9a488901ac4deefd641917424699d98c83fa3</originalsourceid><addsrcrecordid>eNp1kkGP1CAUgInRuOPowT9gmnhxD919FGjhYrIZV51kkrnoxhuhQGe6oaVCO-ve_An-Rn-JjF03rokkLxD4-PJ4PIReYjjDaZwf_LczTICVj9AC04LkQDE8RgsAWuQCoDpBz2K8BgBecPYUnRBSEUoZW6Bm3Q1Kj5lvskGNe7-zfRasmfTY-j7rbNoyMUvLtuum3ju_a7Vy2RD8YMPY2ni8Oe5tttperd_9_P4Di0z7_qCcjdr2YzY4FTv1HD1plIv2xd28RJ_fX35afcw32w_r1cUm1wwXZU5VU9bQgMGGcVY3lVKMVZwoo2uhKOcCsNLUWNuYkmKBK1rQUggjuOakUWSJNrM33thhquUQ2k6FW-lVK900pKhTyGilFiXmBpjklGlJC22kqIWQUPHCEG5JiY-6t7MuuTprjg8Kyj2wPjzp273c-YPkBQMiaBK8uRME_3WycZRdm-rinOqtn6JMWMGhElAm9PU_6LWfQp-qlShGaFGVqRJLdDpTOvgYg23uk8Egj80gUzPI382Q2Fd_Z39P_vn9BJzPwE3r7O3_TfJq-2VW_gIhusAr</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2553427678</pqid></control><display><type>article</type><title>Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kostin, Alexander I. ; Lundgren, Maria N. ; Bulanov, Andrey Y. ; Ladygina, Elena A. ; Chirkova, Karina S. ; Gintsburg, Alexander L. ; Logunov, Denis Y. ; Dolzhikova, Inna V. ; Shcheblyakov, Dmitry V. ; Borovkova, Natalia V. ; Godkov, Mikhail A. ; Bazhenov, Alexey I. ; Shustov, Valeriy V. ; Bogdanova, Alina S. ; Kamalova, Alina R. ; Ganchin, Vladimir V. ; Dombrovskiy, Eugene A. ; Volkov, Stanislav E. ; Drozdova, Nataliya E. ; Petrikov, Sergey S.</creator><creatorcontrib>Kostin, Alexander I. ; Lundgren, Maria N. ; Bulanov, Andrey Y. ; Ladygina, Elena A. ; Chirkova, Karina S. ; Gintsburg, Alexander L. ; Logunov, Denis Y. ; Dolzhikova, Inna V. ; Shcheblyakov, Dmitry V. ; Borovkova, Natalia V. ; Godkov, Mikhail A. ; Bazhenov, Alexey I. ; Shustov, Valeriy V. ; Bogdanova, Alina S. ; Kamalova, Alina R. ; Ganchin, Vladimir V. ; Dombrovskiy, Eugene A. ; Volkov, Stanislav E. ; Drozdova, Nataliya E. ; Petrikov, Sergey S.</creatorcontrib><description>Background and objectives
COVID‐19 convalescent plasma is an experimental treatment against SARS‐CoV‐2. The aim of this study is to assess the impact of different pathogen reduction methods on the levels and virus neutralizing activity of the specific antibodies against SARS‐CoV2 in convalescent plasma.
Materials and methods
A total of 140 plasma doses collected by plasmapheresis from COVID‐19 convalescent donors were subjected to pathogen reduction by three methods: methylene blue (M)/visible light, riboflavin (R)/UVB and amotosalen (A)/UVA. To conduct a paired comparison, individual plasma doses were divided into 2 samples that were subjected to one of these methods. The titres of SARS‐CoV2 neutralizing antibodies (NtAbs) and levels of specific immunoglobulins to RBD, S‐ and N‐proteins of SARS‐CoV‐2 were measured before and after pathogen reduction.
Results
The methods reduced NtAbs titres differently: among units with the initial titre 80 or above, 81% of units remained unchanged and 19% decreased by one step after methylene blue; 60% were unchanged and 40% decreased by one step after amotosalen; after riboflavin 43% were unchanged and 50% (7%, respectively) had a one‐step (two‐step, respectively) decrease. Paired two‐sample comparisons (M vs. A, M vs. R and A vs. R) revealed that the largest statistically significant decrease in quantity and activity of the specific antibodies resulted from the riboflavin treatment.
Conclusion
Pathogen reduction with methylene blue or with amotosalen provides the greater likelihood of preserving the immunological properties of the COVID‐19 convalescent plasma compared to riboflavin.</description><identifier>ISSN: 0042-9007</identifier><identifier>EISSN: 1423-0410</identifier><identifier>DOI: 10.1111/vox.13056</identifier><identifier>PMID: 33734455</identifier><language>eng</language><publisher>England: S. Karger AG</publisher><subject>amotosalen ; Antibodies ; Clinical Medicine ; COVID-19 ; COVID-19 convalescent plasma ; Immunoglobulins ; Immunology ; Infectious Medicine ; Infektionsmedicin ; Klinisk medicin ; Medical and Health Sciences ; Medicin och hälsovetenskap ; Methylene blue ; Neutralizing ; NtAbs ; Original Paper ; Original Papers ; pathogen reduction ; Pathogens ; Plasma ; Plasmapheresis ; Reduction ; Riboflavin ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis ; Statistical methods ; Ultraviolet radiation ; Viruses ; Vitamin B</subject><ispartof>Vox sanguinis, 2021-07, Vol.116 (6), p.665-672</ispartof><rights>2021 International Society of Blood Transfusion</rights><rights>2021 International Society of Blood Transfusion.</rights><rights>Copyright Vox Sanguinis © 2021 International Society of Blood Transfusion</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5126-4af6b0f0d1d585bf7aa55783adcb9a488901ac4deefd641917424699d98c83fa3</citedby><cites>FETCH-LOGICAL-c5126-4af6b0f0d1d585bf7aa55783adcb9a488901ac4deefd641917424699d98c83fa3</cites><orcidid>0000-0001-8081-962X ; 0000-0002-9624-5883 ; 0000-0002-1289-3411 ; 0000-0001-9374-6554 ; 0000-0001-7343-0667 ; 0000-0001-5289-2256 ; 0000-0002-3154-3564 ; 0000-0003-3292-8789 ; 0000-0001-7542-851X ; 0000-0003-2583-9956 ; 0000-0002-6608-8493 ; 0000-0001-8022-8491 ; 0000-0001-9612-6705 ; 0000-0001-9138-6479 ; 0000-0003-1769-5059 ; 0000-0001-6999-8145 ; 0000-0003-2548-6142 ; 0000-0002-8897-7523 ; 0000-0002-1926-145X ; 0000-0003-4035-6581</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fvox.13056$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fvox.13056$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33734455$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/c9618d05-845c-42cd-9b99-0782d38e361a$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Kostin, Alexander I.</creatorcontrib><creatorcontrib>Lundgren, Maria N.</creatorcontrib><creatorcontrib>Bulanov, Andrey Y.</creatorcontrib><creatorcontrib>Ladygina, Elena A.</creatorcontrib><creatorcontrib>Chirkova, Karina S.</creatorcontrib><creatorcontrib>Gintsburg, Alexander L.</creatorcontrib><creatorcontrib>Logunov, Denis Y.</creatorcontrib><creatorcontrib>Dolzhikova, Inna V.</creatorcontrib><creatorcontrib>Shcheblyakov, Dmitry V.</creatorcontrib><creatorcontrib>Borovkova, Natalia V.</creatorcontrib><creatorcontrib>Godkov, Mikhail A.</creatorcontrib><creatorcontrib>Bazhenov, Alexey I.</creatorcontrib><creatorcontrib>Shustov, Valeriy V.</creatorcontrib><creatorcontrib>Bogdanova, Alina S.</creatorcontrib><creatorcontrib>Kamalova, Alina R.</creatorcontrib><creatorcontrib>Ganchin, Vladimir V.</creatorcontrib><creatorcontrib>Dombrovskiy, Eugene A.</creatorcontrib><creatorcontrib>Volkov, Stanislav E.</creatorcontrib><creatorcontrib>Drozdova, Nataliya E.</creatorcontrib><creatorcontrib>Petrikov, Sergey S.</creatorcontrib><title>Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma</title><title>Vox sanguinis</title><addtitle>Vox Sang</addtitle><description>Background and objectives
COVID‐19 convalescent plasma is an experimental treatment against SARS‐CoV‐2. The aim of this study is to assess the impact of different pathogen reduction methods on the levels and virus neutralizing activity of the specific antibodies against SARS‐CoV2 in convalescent plasma.
Materials and methods
A total of 140 plasma doses collected by plasmapheresis from COVID‐19 convalescent donors were subjected to pathogen reduction by three methods: methylene blue (M)/visible light, riboflavin (R)/UVB and amotosalen (A)/UVA. To conduct a paired comparison, individual plasma doses were divided into 2 samples that were subjected to one of these methods. The titres of SARS‐CoV2 neutralizing antibodies (NtAbs) and levels of specific immunoglobulins to RBD, S‐ and N‐proteins of SARS‐CoV‐2 were measured before and after pathogen reduction.
Results
The methods reduced NtAbs titres differently: among units with the initial titre 80 or above, 81% of units remained unchanged and 19% decreased by one step after methylene blue; 60% were unchanged and 40% decreased by one step after amotosalen; after riboflavin 43% were unchanged and 50% (7%, respectively) had a one‐step (two‐step, respectively) decrease. Paired two‐sample comparisons (M vs. A, M vs. R and A vs. R) revealed that the largest statistically significant decrease in quantity and activity of the specific antibodies resulted from the riboflavin treatment.
Conclusion
Pathogen reduction with methylene blue or with amotosalen provides the greater likelihood of preserving the immunological properties of the COVID‐19 convalescent plasma compared to riboflavin.</description><subject>amotosalen</subject><subject>Antibodies</subject><subject>Clinical Medicine</subject><subject>COVID-19</subject><subject>COVID-19 convalescent plasma</subject><subject>Immunoglobulins</subject><subject>Immunology</subject><subject>Infectious Medicine</subject><subject>Infektionsmedicin</subject><subject>Klinisk medicin</subject><subject>Medical and Health Sciences</subject><subject>Medicin och hälsovetenskap</subject><subject>Methylene blue</subject><subject>Neutralizing</subject><subject>NtAbs</subject><subject>Original Paper</subject><subject>Original Papers</subject><subject>pathogen reduction</subject><subject>Pathogens</subject><subject>Plasma</subject><subject>Plasmapheresis</subject><subject>Reduction</subject><subject>Riboflavin</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statistical analysis</subject><subject>Statistical methods</subject><subject>Ultraviolet radiation</subject><subject>Viruses</subject><subject>Vitamin B</subject><issn>0042-9007</issn><issn>1423-0410</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kkGP1CAUgInRuOPowT9gmnhxD919FGjhYrIZV51kkrnoxhuhQGe6oaVCO-ve_An-Rn-JjF03rokkLxD4-PJ4PIReYjjDaZwf_LczTICVj9AC04LkQDE8RgsAWuQCoDpBz2K8BgBecPYUnRBSEUoZW6Bm3Q1Kj5lvskGNe7-zfRasmfTY-j7rbNoyMUvLtuum3ju_a7Vy2RD8YMPY2ni8Oe5tttperd_9_P4Di0z7_qCcjdr2YzY4FTv1HD1plIv2xd28RJ_fX35afcw32w_r1cUm1wwXZU5VU9bQgMGGcVY3lVKMVZwoo2uhKOcCsNLUWNuYkmKBK1rQUggjuOakUWSJNrM33thhquUQ2k6FW-lVK900pKhTyGilFiXmBpjklGlJC22kqIWQUPHCEG5JiY-6t7MuuTprjg8Kyj2wPjzp273c-YPkBQMiaBK8uRME_3WycZRdm-rinOqtn6JMWMGhElAm9PU_6LWfQp-qlShGaFGVqRJLdDpTOvgYg23uk8Egj80gUzPI382Q2Fd_Z39P_vn9BJzPwE3r7O3_TfJq-2VW_gIhusAr</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Kostin, Alexander I.</creator><creator>Lundgren, Maria N.</creator><creator>Bulanov, Andrey Y.</creator><creator>Ladygina, Elena A.</creator><creator>Chirkova, Karina S.</creator><creator>Gintsburg, Alexander L.</creator><creator>Logunov, Denis Y.</creator><creator>Dolzhikova, Inna V.</creator><creator>Shcheblyakov, Dmitry V.</creator><creator>Borovkova, Natalia V.</creator><creator>Godkov, Mikhail A.</creator><creator>Bazhenov, Alexey I.</creator><creator>Shustov, Valeriy V.</creator><creator>Bogdanova, Alina S.</creator><creator>Kamalova, Alina R.</creator><creator>Ganchin, Vladimir V.</creator><creator>Dombrovskiy, Eugene A.</creator><creator>Volkov, Stanislav E.</creator><creator>Drozdova, Nataliya E.</creator><creator>Petrikov, Sergey S.</creator><general>S. Karger AG</general><general>John Wiley and Sons Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D95</scope><orcidid>https://orcid.org/0000-0001-8081-962X</orcidid><orcidid>https://orcid.org/0000-0002-9624-5883</orcidid><orcidid>https://orcid.org/0000-0002-1289-3411</orcidid><orcidid>https://orcid.org/0000-0001-9374-6554</orcidid><orcidid>https://orcid.org/0000-0001-7343-0667</orcidid><orcidid>https://orcid.org/0000-0001-5289-2256</orcidid><orcidid>https://orcid.org/0000-0002-3154-3564</orcidid><orcidid>https://orcid.org/0000-0003-3292-8789</orcidid><orcidid>https://orcid.org/0000-0001-7542-851X</orcidid><orcidid>https://orcid.org/0000-0003-2583-9956</orcidid><orcidid>https://orcid.org/0000-0002-6608-8493</orcidid><orcidid>https://orcid.org/0000-0001-8022-8491</orcidid><orcidid>https://orcid.org/0000-0001-9612-6705</orcidid><orcidid>https://orcid.org/0000-0001-9138-6479</orcidid><orcidid>https://orcid.org/0000-0003-1769-5059</orcidid><orcidid>https://orcid.org/0000-0001-6999-8145</orcidid><orcidid>https://orcid.org/0000-0003-2548-6142</orcidid><orcidid>https://orcid.org/0000-0002-8897-7523</orcidid><orcidid>https://orcid.org/0000-0002-1926-145X</orcidid><orcidid>https://orcid.org/0000-0003-4035-6581</orcidid></search><sort><creationdate>202107</creationdate><title>Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma</title><author>Kostin, Alexander I. ; Lundgren, Maria N. ; Bulanov, Andrey Y. ; Ladygina, Elena A. ; Chirkova, Karina S. ; Gintsburg, Alexander L. ; Logunov, Denis Y. ; Dolzhikova, Inna V. ; Shcheblyakov, Dmitry V. ; Borovkova, Natalia V. ; Godkov, Mikhail A. ; Bazhenov, Alexey I. ; Shustov, Valeriy V. ; Bogdanova, Alina S. ; Kamalova, Alina R. ; Ganchin, Vladimir V. ; Dombrovskiy, Eugene A. ; Volkov, Stanislav E. ; Drozdova, Nataliya E. ; Petrikov, Sergey S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5126-4af6b0f0d1d585bf7aa55783adcb9a488901ac4deefd641917424699d98c83fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>amotosalen</topic><topic>Antibodies</topic><topic>Clinical Medicine</topic><topic>COVID-19</topic><topic>COVID-19 convalescent plasma</topic><topic>Immunoglobulins</topic><topic>Immunology</topic><topic>Infectious Medicine</topic><topic>Infektionsmedicin</topic><topic>Klinisk medicin</topic><topic>Medical and Health Sciences</topic><topic>Medicin och hälsovetenskap</topic><topic>Methylene blue</topic><topic>Neutralizing</topic><topic>NtAbs</topic><topic>Original Paper</topic><topic>Original Papers</topic><topic>pathogen reduction</topic><topic>Pathogens</topic><topic>Plasma</topic><topic>Plasmapheresis</topic><topic>Reduction</topic><topic>Riboflavin</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statistical analysis</topic><topic>Statistical methods</topic><topic>Ultraviolet radiation</topic><topic>Viruses</topic><topic>Vitamin B</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kostin, Alexander I.</creatorcontrib><creatorcontrib>Lundgren, Maria N.</creatorcontrib><creatorcontrib>Bulanov, Andrey Y.</creatorcontrib><creatorcontrib>Ladygina, Elena A.</creatorcontrib><creatorcontrib>Chirkova, Karina S.</creatorcontrib><creatorcontrib>Gintsburg, Alexander L.</creatorcontrib><creatorcontrib>Logunov, Denis Y.</creatorcontrib><creatorcontrib>Dolzhikova, Inna V.</creatorcontrib><creatorcontrib>Shcheblyakov, Dmitry V.</creatorcontrib><creatorcontrib>Borovkova, Natalia V.</creatorcontrib><creatorcontrib>Godkov, Mikhail A.</creatorcontrib><creatorcontrib>Bazhenov, Alexey I.</creatorcontrib><creatorcontrib>Shustov, Valeriy V.</creatorcontrib><creatorcontrib>Bogdanova, Alina S.</creatorcontrib><creatorcontrib>Kamalova, Alina R.</creatorcontrib><creatorcontrib>Ganchin, Vladimir V.</creatorcontrib><creatorcontrib>Dombrovskiy, Eugene A.</creatorcontrib><creatorcontrib>Volkov, Stanislav E.</creatorcontrib><creatorcontrib>Drozdova, Nataliya E.</creatorcontrib><creatorcontrib>Petrikov, Sergey S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Lunds universitet</collection><jtitle>Vox sanguinis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kostin, Alexander I.</au><au>Lundgren, Maria N.</au><au>Bulanov, Andrey Y.</au><au>Ladygina, Elena A.</au><au>Chirkova, Karina S.</au><au>Gintsburg, Alexander L.</au><au>Logunov, Denis Y.</au><au>Dolzhikova, Inna V.</au><au>Shcheblyakov, Dmitry V.</au><au>Borovkova, Natalia V.</au><au>Godkov, Mikhail A.</au><au>Bazhenov, Alexey I.</au><au>Shustov, Valeriy V.</au><au>Bogdanova, Alina S.</au><au>Kamalova, Alina R.</au><au>Ganchin, Vladimir V.</au><au>Dombrovskiy, Eugene A.</au><au>Volkov, Stanislav E.</au><au>Drozdova, Nataliya E.</au><au>Petrikov, Sergey S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma</atitle><jtitle>Vox sanguinis</jtitle><addtitle>Vox Sang</addtitle><date>2021-07</date><risdate>2021</risdate><volume>116</volume><issue>6</issue><spage>665</spage><epage>672</epage><pages>665-672</pages><issn>0042-9007</issn><eissn>1423-0410</eissn><abstract>Background and objectives
COVID‐19 convalescent plasma is an experimental treatment against SARS‐CoV‐2. The aim of this study is to assess the impact of different pathogen reduction methods on the levels and virus neutralizing activity of the specific antibodies against SARS‐CoV2 in convalescent plasma.
Materials and methods
A total of 140 plasma doses collected by plasmapheresis from COVID‐19 convalescent donors were subjected to pathogen reduction by three methods: methylene blue (M)/visible light, riboflavin (R)/UVB and amotosalen (A)/UVA. To conduct a paired comparison, individual plasma doses were divided into 2 samples that were subjected to one of these methods. The titres of SARS‐CoV2 neutralizing antibodies (NtAbs) and levels of specific immunoglobulins to RBD, S‐ and N‐proteins of SARS‐CoV‐2 were measured before and after pathogen reduction.
Results
The methods reduced NtAbs titres differently: among units with the initial titre 80 or above, 81% of units remained unchanged and 19% decreased by one step after methylene blue; 60% were unchanged and 40% decreased by one step after amotosalen; after riboflavin 43% were unchanged and 50% (7%, respectively) had a one‐step (two‐step, respectively) decrease. Paired two‐sample comparisons (M vs. A, M vs. R and A vs. R) revealed that the largest statistically significant decrease in quantity and activity of the specific antibodies resulted from the riboflavin treatment.
Conclusion
Pathogen reduction with methylene blue or with amotosalen provides the greater likelihood of preserving the immunological properties of the COVID‐19 convalescent plasma compared to riboflavin.</abstract><cop>England</cop><pub>S. Karger AG</pub><pmid>33734455</pmid><doi>10.1111/vox.13056</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8081-962X</orcidid><orcidid>https://orcid.org/0000-0002-9624-5883</orcidid><orcidid>https://orcid.org/0000-0002-1289-3411</orcidid><orcidid>https://orcid.org/0000-0001-9374-6554</orcidid><orcidid>https://orcid.org/0000-0001-7343-0667</orcidid><orcidid>https://orcid.org/0000-0001-5289-2256</orcidid><orcidid>https://orcid.org/0000-0002-3154-3564</orcidid><orcidid>https://orcid.org/0000-0003-3292-8789</orcidid><orcidid>https://orcid.org/0000-0001-7542-851X</orcidid><orcidid>https://orcid.org/0000-0003-2583-9956</orcidid><orcidid>https://orcid.org/0000-0002-6608-8493</orcidid><orcidid>https://orcid.org/0000-0001-8022-8491</orcidid><orcidid>https://orcid.org/0000-0001-9612-6705</orcidid><orcidid>https://orcid.org/0000-0001-9138-6479</orcidid><orcidid>https://orcid.org/0000-0003-1769-5059</orcidid><orcidid>https://orcid.org/0000-0001-6999-8145</orcidid><orcidid>https://orcid.org/0000-0003-2548-6142</orcidid><orcidid>https://orcid.org/0000-0002-8897-7523</orcidid><orcidid>https://orcid.org/0000-0002-1926-145X</orcidid><orcidid>https://orcid.org/0000-0003-4035-6581</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0042-9007 |
| ispartof | Vox sanguinis, 2021-07, Vol.116 (6), p.665-672 |
| issn | 0042-9007 1423-0410 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8250394 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | amotosalen Antibodies Clinical Medicine COVID-19 COVID-19 convalescent plasma Immunoglobulins Immunology Infectious Medicine Infektionsmedicin Klinisk medicin Medical and Health Sciences Medicin och hälsovetenskap Methylene blue Neutralizing NtAbs Original Paper Original Papers pathogen reduction Pathogens Plasma Plasmapheresis Reduction Riboflavin Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Statistical analysis Statistical methods Ultraviolet radiation Viruses Vitamin B |
| title | Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T22%3A09%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20pathogen%20reduction%20methods%20on%20immunological%20properties%20of%20the%20COVID%E2%80%9019%20convalescent%20plasma&rft.jtitle=Vox%20sanguinis&rft.au=Kostin,%20Alexander%20I.&rft.date=2021-07&rft.volume=116&rft.issue=6&rft.spage=665&rft.epage=672&rft.pages=665-672&rft.issn=0042-9007&rft.eissn=1423-0410&rft_id=info:doi/10.1111/vox.13056&rft_dat=%3Cproquest_swepu%3E2553427678%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2553427678&rft_id=info:pmid/33734455&rfr_iscdi=true |